Om

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I WAVE LIFE SCIENCES MED ENDAVU: Køb Wave Life Sciences ($WVE) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Wave Life Sciences, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.